Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: PharmaSwiss ฤeskรก republika s.r.o., Jankovcova 1569/2c, 170 00, Prague 7, Czech Republic
Megace is a progestational agent, indicated for the treatment of certain hormone dependent neoplasms, such as breast cancer.
160 mg/day taken once daily.
At least two months of continuous treatment is considered an adequate period for determining the efficacy of Megace.
Safety and effectiveness in paediatric patients have not been established.
Megace is not recommended for use in children.
In general, use in elderly patients should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. See section 4.4.
No acute toxicological effects have resulted from studies involving Megace (megestrol acetate) administered in dosages as high as 1600 mg/day for six months or more.
Reports of overdose have also been received in the postmarketing setting. Signs and symptoms reported in the context of overdose included diarrhoea, nausea, abdominal pain, shortness of breath, cough, unsteady gait, listlessness, and chest pain. There is no specific antidote for overdose with Megace. In case of overdose, appropriate supportive measures should be taken.
Shelf life:
Do not store Megace Tablets above 25ยฐC. Store in the original package in order to protect from moisture.
Amber glass bottles of 30, 60 or 100.
Blister packs of 30 tablets.
No special requirements.
ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
